For Immediate Release: March 12, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the […]

Allergic rhinitis — also known as hay fever — is a very common condition that occurs as an inflammatory response to a person breathing in an […]

Generally, patients prefer to take drugs by mouth (orally).1 Solid oral drugs, such as capsules and tablets, are common because they are cost-effective to make, and […]

Frailty is an aging-related syndrome of cumulative physical and physiological decline, which can include symptoms such as weakness and fatigue, greater medical complications, and lower tolerance […]

FDA Research Focused on Direct-to-Consumer Television Advertising Clinical endpoints are measurable events or outcomes that can help determine whether a medical intervention, such as a therapy, […]

A biosimilar product (biosimilar) is highly similar to, and has no clinically meaningful differences from, an FDA-approved reference product. Biosimilars may spur competition and result in […]

CDER investigates the utility of a text messaging app to obtain patient-reported information that can help FDA improve opioid prescription guidelines for surgical patients. The Public […]

Contributed by Shetarra Walker, MD, MSCR, Lead Physician and Clinical Team Leader, Office of Rare Disease, Pediatrics, Urologic and Reproductive Medicine, CDER, and Salim F. Idriss, […]

Ranitidine, which blocks histamine-induced acid secretion in the stomach, was approved in 1983. It became widely used over the ensuing decades as a prescription and over-the-counter […]